{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:27:10Z","timestamp":1781893630033,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010353","name":"Hellenic Atherosclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clnu.2024.10.020","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T10:32:38Z","timestamp":1729074758000},"page":"84-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The effect of lipid-lowering treatment on indices of MASLD in familial hypercholesterolemia patients"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0053-2440","authenticated-orcid":false,"given":"Chrysoula","family":"Boutari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos V.","family":"Rizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Liamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Skoumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loukianos","family":"Rallidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Garoufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa","family":"Kolovou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sfikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tziomalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Skalidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Kotsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalis","family":"Doumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimon","family":"Stamatelopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaia","family":"Lambadiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Anagnostis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Boufidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Giannakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermioni","family":"Petkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Vlachopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Fakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos A.","family":"Papathanasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilleas","family":"Attilakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vana","family":"Kolovou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Koumaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Agapakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Zacharis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Antza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralampos","family":"Milionis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Liberopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3755-8158","authenticated-orcid":false,"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnu.2024.10.020_bib1","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/liv.15674","article-title":"The NAFLD burden on mortality and morbidities in general population: a community-based longitudinal study (NASH-CO study)","volume":"43","author":"Nabi","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.clnu.2024.10.020_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s13679-024-00574-z","article-title":"Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD","volume":"13","author":"Abdelhameed","year":"2024","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.clnu.2024.10.020_bib3","article-title":"The triglyceride and glucose index is a predictor of incident nonalcoholic fatty liver disease: a population-based cohort study","volume":"2019","author":"Kitae","year":"2019","journal-title":"Chin J Gastroenterol Hepatol"},{"key":"10.1016\/j.clnu.2024.10.020_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","article-title":"The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement","volume":"71","author":"Athyros","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.clnu.2024.10.020_bib5","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.clnu.2022.08.001","article-title":"Statins' efficacy in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"41","author":"Boutari","year":"2022","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnu.2024.10.020_bib6","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.2174\/1381612824666181010123127","article-title":"The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors","volume":"24","author":"Theocharidou","year":"2018","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.clnu.2024.10.020_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clnu.2024.10.020_bib8","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2174\/1381612827666210216151645","article-title":"Prevalence of non-coronary heart disease in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH","volume":"27","author":"Anagnostis","year":"2021","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.clnu.2024.10.020_bib9","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jacl.2023.05.081","article-title":"Patients with familial hypercholesterolemia with non-alcoholic fatty liver disease have worse clinical outcomes, Nation-Wide study","volume":"17","author":"Khokhlov","year":"2023","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.clnu.2024.10.020_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2019.06.501","article-title":"Prevalence of fatty liver and its association with cardiovascular disease in patients with familial hypercholesterolemia","volume":"287","author":"Lugari","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clnu.2024.10.020_bib11","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1016\/j.atherosclerosis.2021.06.621","article-title":"Non-alcoholic fatty liver disease and subclinical atherosclerosis in a population affected by familial hypercholesterolemia","volume":"331","author":"Mondelli","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clnu.2024.10.020_bib12","first-page":"1","article-title":"Atherosclerosis VA-HJ \u03bff, 2018 U. PCSK9 administration ameliorates non alcoholic fatty disease in patients with heterozygous familial hyperlipidemia","volume":"9","author":"Dimakopoulou","year":"2018","journal-title":"Hell J Atheroscler"},{"key":"10.1016\/j.clnu.2024.10.020_bib13","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.numecd.2020.11.009","article-title":"Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: a single lipid center real-world experience","volume":"31","author":"Scicali","year":"2021","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.clnu.2024.10.020_bib14","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.4254\/wjh.v12.i12.1258","article-title":"Effects of proprotein convertase subtilisin\/kexin type-9 inhibitors on fatty liver","volume":"12","author":"Shafiq","year":"2020","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clnu.2024.10.020_bib15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF03401525","article-title":"An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH)","volume":"16","author":"Rizos","year":"2017","journal-title":"Hormones (Basel)"},{"key":"10.1016\/j.clnu.2024.10.020_bib16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.atherosclerosis.2018.08.017","article-title":"Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH)","volume":"277","author":"Rizos","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clnu.2024.10.020_bib17","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjcard.2008.06.056","article-title":"Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia","volume":"102","author":"Civeira","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clnu.2024.10.020_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.clnu.2024.10.020_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155666","article-title":"Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: results from a large multi-center study","volume":"147","author":"Kouvari","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.clnu.2024.10.020_bib20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1515\/jpem-2019-0579","article-title":"The correct formula to calculate triglyceride-glucose index (TyG)","volume":"33","author":"Alizargar","year":"2020","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"key":"10.1016\/j.clnu.2024.10.020_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-017-0409-6","article-title":"The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease","volume":"16","author":"Zhang","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clnu.2024.10.020_bib22","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.clnu.2024.10.020_bib23","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.2337\/dc24-S010","article-title":"10. Cardiovascular disease and risk management: standards of Care in diabetes\u20142024","volume":"47","author":"Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnu.2024.10.020_bib24","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A\u00a0multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clnu.2024.10.020_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4254\/wjh.v14.i1.119","article-title":"Is there a role of lipid-lowering therapies in the management of fatty liver disease?","volume":"14","author":"Tzanaki","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clnu.2024.10.020_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2024.01.005","article-title":"Obesity and atherosclerotic cardiovascular disease in adults with heterozygous familial hypercholesterolemia: an analysis from HELLAS-FH registry","author":"Barkas","year":"2024","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.clnu.2024.10.020_bib27","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clnu.2024.10.020_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/liv.14711","article-title":"PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD","volume":"41","author":"Grimaudo","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.clnu.2024.10.020_bib29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/hep4.1858","article-title":"Pcsk9 deletion promotes murine nonalcoholic steatohepatitis and hepatic carcinogenesis: role of cholesterol","volume":"6","author":"Ioannou","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.clnu.2024.10.020_bib30","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1177\/2047487317724342","article-title":"PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans","volume":"24","author":"Baragetti","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.clnu.2024.10.020_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clinbiochem.2020.01.003","article-title":"Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis","volume":"77","author":"Paquette","year":"2020","journal-title":"Clin Biochem"},{"key":"10.1016\/j.clnu.2024.10.020_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155220","article-title":"Nonalcoholic fatty liver disease and cardiovascular diseases: a Mendelian randomization study","volume":"133","author":"Peng","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.clnu.2024.10.020_bib33","article-title":"Hepatic and circulating levels of PCSK9 in morbidly obese patients: relation with severity of liver steatosis","volume":"1865","author":"Emma","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.clnu.2024.10.020_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2018.09.008","article-title":"Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population","volume":"278","author":"Wargny","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clnu.2024.10.020_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/JCI141513","article-title":"Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis","volume":"131","author":"He","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clnu.2024.10.020_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics14070762","article-title":"Diagnostic accuracy of the triglyceride-glucose index (TyG), TyG body mass index, and TyG waist circumference index for liver steatosis detection","volume":"14","author":"Mijangos-Trejo","year":"2024","journal-title":"Diagnostics"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561424003789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561424003789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T12:22:14Z","timestamp":1738412534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561424003789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0261561424003789"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2024.10.020","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of lipid-lowering treatment on indices of MASLD in familial hypercholesterolemia patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2024.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}